Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.51 |
| ▸ | FUCA1 | P04066 | 5/20 | 0.46 |
| ▸ | GBA1 | P04062 | 5/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | GLB1 | P16278 | 1/20 | 0.46 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.40 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15521093 | 1.00 | OGA (0.51) | OGAFUCA1GBA1GLAGAA | |
| SCHEMBL2272527 | 1.00 | OGA (0.51) | OGAFUCA1GBA1GLAGAA | |
| SCHEMBL15521047 | 1.00 | OGA (0.51) | OGAFUCA1GBA1GLAGAA | |
| SCHEMBL14426738 | 0.94 | FUCA1 (0.50) | OGAFUCA1GBA1GLAGAA | |
| SCHEMBL28894746 | 0.88 | OGA (0.46) | OGAFUCA1GBA1GLAGAA | |
| SCHEMBL2244048 | 0.88 | OGA (0.46) | OGAFUCA1GBA1GLAGAA | |
| SCHEMBL2202667 | 0.88 | OGA (0.46) | OGAFUCA1GBA1GLAGAA | |
| SCHEMBL2202670 | 0.88 | OGA (0.46) | OGAFUCA1GBA1GLAGAA | |
| SCHEMBL2202664 | 0.88 | OGA (0.46) | OGAFUCA1GBA1GLAGAA | |
| Hydrochloric Acid SCHEMBL2201669 | 0.86 | OGA (0.44) | OGAFUCA1GBA1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522883-B2 | Glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2016-12-20 | — | — | US | disclosed |
| US-9522883-B2 | Glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2016-12-20 | — | — | US | disclosed |
| US-20150218097-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-08-06 | — | — | US | disclosed |
| US-20150218097-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-08-06 | — | — | US | disclosed |
| WO-2014032187-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2014-03-06 | — | — | WO | disclosed |
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | SUMMIT CORPORATION PLC (GB) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | GAA, MAN2B1, GBA1 | OGA 51/4885FUCA1 17/4885GBA1 3/4885 |
| US-20150218097-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | GAA, ENGASE, OGA | OGA 3/4885FUCA1 34/4885GBA1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.